Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil in Scleroderma-Associated ILD
NCT01553981Phase 3Completed
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Start
- Mar 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in interstitial lung disease (ILD) and systemic sclerosis (SSc) comparing Tadalafil with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 6 months. Started Mar 2012; status: completed.
02
Drugs
tadalafil
03
Conditions
interstitial lung disease (ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01553981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553981.